1326 GMT - Bayer's fourth-quarter results showed some positive surprises, but challenges to the company's underlying performance remain, Deutsche Bank analysts write. Fourth quarter sales, adjusted EBITDA and adjusted EPS exceeded expectations, largely due to slightly better-than-expected sales in all three units, along with lower corporate costs. However, underlying results reveal a different picture, with flat organic sales, a 22% decline in adjusted EBITDA and a 43% drop in adjusted EPS. 2025 guidance is not particularly encouraging, but the company's longer-term outlook and plans to address key issues offer some hope for future improvement, they add. "Investors will likely need to exercise patience as these measures take time to yield results." Deutsche Bank has a hold rating and 23 euro target price for Bayer's shares. Shares rise 3.5% at 24.35 euros. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 08:26 ET (13:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.